Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

BioMarin Pharmaceutical Inc. - Common Stock (NQ:BMRN)

68.32 +0.38 (+0.56%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioMarin Pharmaceutical Inc. - Common Stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
The Daily Biotech Pulse: Kodiak Sinks On Adverse Study Outcome, Marinus Flags Delay In Clinical Trial, Mainz Biomed Gains On Positive Regulatory Development
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kodiak's Wet AMD Treatment KSI-301 Did Not Meet Primary Endpoint In Phase... 
Via Benzinga
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front... 
Via Benzinga
BioMarin Stock Dives As FDA Questions The Safety Of Its Gene Therapy
BioMarin needs to run additional testing in animal models for its PKU gene therapy. 
Via Investor's Business Daily
FDA Asks For More Data To Resolve BioMarin's Gene Therapy Clinical Hold
BioMarin Pharmaceutical Inc (NASDAQ: BMRN) said that the FDA had requested additional information regarding the clinical hold on PHEARLESS Phase 1/2 study of BMN... 
Via Benzinga
BioMarin Sells Priority Review Voucher For $110M
BioMarin Pharmaceutical Inc (NASDAQ: BMRN) has agreed to sell the Rare Pediatric Disease Priority Review Voucher (PRV)  
Via Benzinga
Bear Market Bets In Biotech
Taken together, the SPDR S&P Biotech ETF easily broke below the long-term 200-week support for the first time since the pandemic originally hit the markets in March of 2020. 
Via Talk Markets
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of BioMarin Pharmaceutical Inc.
Wilmington, Delaware--(Newsfile Corp. - February 3, 2022) - Rigrodsky Law, P.A. is investigating potential claims against the officers and directors... 
Via Newsfile
Exposures Product Safety
Futures Resume Tumbling After Yields Spike To New 2 Year High
US index futures traded down to session lows as US traders sat at their desks after rising modestly earlier in the session, and were down 27 points or 0.6% at 730am. 
Via Talk Markets
BIOMARIN CLASS ACTION REMINDER
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal Product Safety
BioMarin's Hemophilia Gene Therapy Meets Efficacy Endpoints At Two Year Analysis
BioMarin Pharmaceutical Inc (NASDAQ: BMRN) announced results from its ongoing Phase 3 GENEr8-1 study of valoctocogene roxaparvovec, investigational gene therapy for severe... 
Via Benzinga
BioMarin Class Action Reminder
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
BioMarin Shareholder Notice
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
BioMarin Shareholder Alert
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
BioMarin Deadline Alert
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
BioMarin Deadline Alert
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
BioMarin Deadline Alert
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Final Deadline Alert - Bronstein, Gewirtz & Grossman, LLC Reminds BioMarin Pharmaceutical Inc. (BMRN) Investors of Class Action
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Deadline Tomorrow Alert: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against BioMarin Pharmaceutical Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Deadline Notice: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against BioMarin Pharmaceutical Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
TUESDAY DEADLINE NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against BioMarin Pharmaceutical Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Los Angeles - (NewMediaWire) - December 16, 2021 - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioMarin Pharmaceutical Inc.... 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
TUESDAY DEADLINE REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against BioMarin Pharmaceutical Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
BIOMARIN UPDATE
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal Product Safety
BIOMARIN SHAREHOLDER NOTICE
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal Product Safety
BIOMARIN SHAREHOLDER ALERT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal Product Safety
BIOMARIN DEADLINE ALERT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal Product Safety
BIOMARIN UPDATE
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal Product Safety
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against BioMarin Pharmaceutical Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
LOS ANGELES, CA - (NewMediaWire) - December 4, 2021 - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioMarin Pharmaceutical... 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal Product Safety
BIOMARIN CLASS ACTION REMINDER
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal Product Safety
BIOMARIN SHAREHOLDER NOTICE
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal Product Safety
BIOMARIN SHAREHOLDER ALERT
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In BioMarin To Contact Him Directly To Discuss Their Options 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal Product Safety
< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.